Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Company Deals

Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Fineline Cube Jun 25, 2026
Company Drug

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

Fineline Cube Jun 25, 2026
Company Deals

Mabwell and DP Technology Collaborate to Build Biopharma AI Platform for Drug Development

Fineline Cube Apr 14, 2025

Chinese companies Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) and DP Technology have entered into...

Company Drug

Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment

Fineline Cube Apr 14, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...

Company Deals

Jiangxi Institute of Biological Products Files for Hong Kong IPO Amid Strong Market Position

Fineline Cube Apr 14, 2025

Jiangxi Institute of Biological Products Inc., China’s largest provider and exporter of human tetanus antitoxin...

Company Deals Drug

Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment

Fineline Cube Apr 14, 2025

Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of SYH2046 in Heart Failure

Fineline Cube Apr 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer

Fineline Cube Apr 14, 2025

US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...

Company Medical Device

Shanghai Microport EP Medtech Secures NMPA Fast-Track Designation for EasyEcho Catheter

Fineline Cube Apr 14, 2025

China’s Shanghai Microport EP Medtech Co., Ltd (SHA: 688351) has announced that it has received...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-3792 and HRS-9190

Fineline Cube Apr 14, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received separate...

Company Drug

Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer

Fineline Cube Apr 14, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...

Company Drug

Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma

Fineline Cube Apr 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...

Company Drug

CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin

Fineline Cube Apr 14, 2025

China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...

Company

Novartis Announces USD 23 Billion Investment to Expand U.S. Manufacturing and R&D Hubs

Fineline Cube Apr 11, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced plans to invest USD 23 billion over...

Company Drug

Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA

Fineline Cube Apr 11, 2025

Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...

Company Drug

Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy

Fineline Cube Apr 11, 2025

China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...

Company Drug

Zai Lab’s Partner argenx Secures FDA Approval for Vygart Hytrulo Prefilled Syringe in gMG and CIDP

Fineline Cube Apr 11, 2025

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) and its Dutch partner argenx SE (NASDAQ:...

Company Deals

Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology

Fineline Cube Apr 11, 2025

France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG...

Company Deals Medical Device

INTCO Medical and JD Healthcare Partner to Innovate ‘Internet + Healthcare’ Service Models

Fineline Cube Apr 11, 2025

China-based INTCO Medical (SHE: 300677), a high-tech manufacturer of medical consumables and equipment, has entered...

Company Medical Device

KingstronBio’s Prostyle A Valve Gains NMPA Approval, Setting New Benchmark in Transcatheter Aortic Valve Replacement

Fineline Cube Apr 11, 2025

KingstronBio, a Changshu-based structural heart disease device manufacturer, has obtained marketing approval from China’s National...

Company Deals

iRegene Therapeutics Secures RMB 100 Million in Series B+ Financing to Advance iPSC Technology

Fineline Cube Apr 11, 2025

Wuhan-based iRegene Therapeutics, a pioneer in AI-powered, chemically induced cell therapies, has reportedly raised close...

Company

Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs

Fineline Cube Apr 11, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...

Posts pagination

1 … 200 201 202 … 687

Recent updates

  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
  • AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six
  • YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders
  • Sanofi’s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Company Drug

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

Company Drug

AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six

Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.